

Valder R Arruda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6271803/publications.pdf>

Version: 2024-02-01

109
papers

11,700
citations

76294

40
h-index

60583

81
g-index

109
all docs

109
docs citations

109
times ranked

6510
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitorsâ€”Recent insights. <i>Haemophilia</i> , 2021, 27, 28-36.	1.0	6
2	Gene Therapy for Inherited Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 161-173.	1.5	11
3	Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IXâ€”Padua. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1212-1218.	1.9	17
4	Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. <i>Blood Advances</i> , 2021, 5, 1324-1332.	2.5	12
5	B cellâ€”activating factor modulates the factor VIII immune response in hemophilia A. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	10
6	Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?. <i>Blood Advances</i> , 2021, 5, 4313-4313.	2.5	2
7	Extra-Splenic Role of B Cell Activating Factor Blockade in Prevention of Factor VIII Inhibitors. <i>Blood</i> , 2021, 138, 1025-1025.	0.6	0
8	Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 1129-1138.	1.8	34
9	Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020069.	0.5	18
10	Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A. <i>Frontiers in Immunology</i> , 2020, 11, 618.	2.2	22
11	Gene therapy for hemophilia: Progress to date and challenges moving forward. <i>Transfusion and Apheresis Science</i> , 2019, 58, 602-612.	0.5	23
12	Gene therapy matures to medicines. <i>Human Molecular Genetics</i> , 2019, 28, R1-R2.	1.4	1
13	Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 184-201.	1.8	39
14	Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. <i>JCI Insight</i> , 2019, 4, .	2.3	24
15	Emerging therapies for hemophilia: controversies and unanswered questions. <i>F1000Research</i> , 2018, 7, 489.	0.8	29
16	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa. <i>Thrombosis Research</i> , 2018, 170, 133-141.	0.8	5
17	Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. <i>Blood Advances</i> , 2018, 2, 505-508.	2.5	21
18	Gene therapy for hemophilia: what does the future hold?. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 273-293.	1.1	79

#	ARTICLE	IF	CITATIONS
19	The Complete Dependence of Factor IX Padua (R338L) Hyperactivity on Factor VIIIa Cofactor Activity Supports Its Safety As a Transgene for Hemophilia B Gene Therapy. <i>Blood</i> , 2018, 132, 3486-3486.	0.6	0
20	A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. <i>Molecular Therapy</i> , 2017, 25, 1815-1830.	3.7	52
21	Novel approaches to hemophilia therapy: successes and challenges. <i>Blood</i> , 2017, 130, 2251-2256.	0.6	95
22	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>New England Journal of Medicine</i> , 2017, 377, 2215-2227.	13.9	549
23	Stopping bleeding is not enough to FIX hemarthropathy. <i>Blood</i> , 2017, 129, 2048-2049.	0.6	0
24	Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. <i>JCI Insight</i> , 2016, 1, e89371.	2.3	28
25	Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs. <i>PLoS ONE</i> , 2016, 11, e0151800.	1.1	25
26	Infusion of Coagulation Factor VIII-Containing Induced Pluripotent Stem Cell (iPSC)-Derived Megakaryocytes (iMks) Shows Potential As Hemophilia a Treatment. <i>Blood</i> , 2016, 128, 2559-2559.	0.6	0
27	Factor IX Padua: From Biochemistry to Gene Therapy. <i>Blood</i> , 2016, 128, SCI-9-SCI-9.	0.6	1
28	The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A. <i>Haematologica</i> , 2015, 100, 849-850.	1.7	16
29	Obstacles and future of gene therapy for hemophilia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 997-1010.	0.5	28
30	AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. <i>Blood</i> , 2015, 125, 1553-1561.	0.6	143
31	Complete Correction of Severe Canine Hemophilia B By Skeletal Muscle Directed AAV-Based FIX-Padua Gene Therapy in Inhibitor-Prone Dogs. <i>Blood</i> , 2015, 126, 3487-3487.	0.6	1
32	Towards the Care of Hemophilia a Patients Using Induced Pluripotent Stem Cell (iPSC)-Derived Megakaryocytes (iMks) Expressing Coagulation Factor (F) VIII. <i>Blood</i> , 2015, 126, 2266-2266.	0.6	0
33	Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. <i>Blood</i> , 2014, 123, 4045-4053.	0.6	28
34	Unexpected Role of PACE/Furin Cleavage Site in FVIII Biology: Implications for Hemophilia a Therapy. <i>Blood</i> , 2014, 124, 105-105.	0.6	1
35	VKORc1 Is Under-Expressed in Skeletal Muscle of Humans, Dogs and Mice: Potential Implications for Ectopic Coagulation Factor Expression in Pre-Clinical and Therapeutic Applications. <i>Blood</i> , 2014, 124, 1477-1477.	0.6	0
36	Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. <i>Blood</i> , 2013, 121, 4396-4403.	0.6	70

#	ARTICLE	IF	CITATIONS
37	Muscle Gene Therapy for Hemophilia. <i>Journal of Genetic Syndromes & Gene Therapy</i> , 2013, S1, .	0.2	1
38	Tolerance Induction To FIX Padua With AAV Liver Gene Transfer In Inhibitor-Prone Hemophilia B Dogs. <i>Blood</i> , 2013, 122, 4203-4203.	0.6	0
39	The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. <i>Blood</i> , 2012, 120, 4521-4523.	0.6	100
40	Insights Into the Mechanism of Zymogen Protein C Protection Against Cancer Progression. <i>Blood</i> , 2012, 120, 3350-3350.	0.6	1
41	Bioengineering Factor VIII B-Domain Sequences Improves Function and Efficacy in Hemophilia A Models. <i>Blood</i> , 2012, 120, 2208-2208.	0.6	0
42	Delivery of a Modified U1 Small Nuclear RNA Alleviates Splicing-Defective Coagulation Factor VII Expression in Mouse Models. <i>Blood</i> , 2012, 120, 754-754.	0.6	0
43	Platelet Factor VIII-Induced Megakaryocyte Apoptosis: Implications for Hemophilia A Gene Therapy. <i>Blood</i> , 2012, 120, 2051-2051.	0.6	0
44	Safety of Liver Gene Transfer Following Peripheral Intravascular Delivery of Adeno-Associated Virus (AAV)-5 and AAV-6 in a Large Animal Model. <i>Human Gene Therapy</i> , 2011, 22, 843-852.	1.4	25
45	Assessing the potential for AAV vector genotoxicity in a murine model. <i>Blood</i> , 2011, 117, 3311-3319.	0.6	196
46	Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors. <i>Molecular Therapy</i> , 2011, 19, 442-449.	3.7	116
47	Protease-Activated Receptor 4 (PAR4) Plays a Critical Role in Fetal Loss and Peripheral Thrombosis in a Mouse Model of Thrombophilia. <i>Blood</i> , 2011, 118, 373-373.	0.6	0
48	Hemophilia Gene Therapy. <i>Blood</i> , 2011, 118, SCI-48-SCI-48.	0.6	0
49	The Role of Activated Protein C in Cancer. <i>Blood</i> , 2011, 118, SCI-18-SCI-18.	0.6	0
50	Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. <i>Blood</i> , 2010, 115, 4678-4688.	0.6	104
51	Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. <i>Blood</i> , 2010, 116, 5842-5848.	0.6	144
52	In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. <i>Blood</i> , 2010, 116, 6114-6122.	0.6	54
53	Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs. <i>Molecular Therapy</i> , 2010, 18, 1318-1329.	3.7	66
54	Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques. <i>Blood</i> , 2010, 116, 3765-3765.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Naturally-Occurring Antibodies to Human AAV In Sheep: A New Large Animal Model for Immune Aspects of AAV Gene Transfer.. Blood, 2010, 116, 3762-3762.	0.6	0
56	Understanding Ectopically Expressed Factor VIII (F8) In Megakaryocytes: Implications for Optimum Platelet-Delivered F8 Activity for Gene Therapy. Blood, 2010, 116, 2205-2205.	0.6	4
57	Zymogen Protein C as a Novel Modulator of Cancer Progression In Murine Models. Blood, 2010, 116, 718-718.	0.6	0
58	X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). New England Journal of Medicine, 2009, 361, 1671-1675.	13.9	298
59	Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy. Molecular Therapy, 2009, 17, 1492-1503.	3.7	56
60	Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009, 113, 797-806.	0.6	247
61	Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood, 2009, 114, 4562-4565.	0.6	55
62	FIX-R338L (FIX Padua) as a Successful Alternative for the Treatment of Canine Severe Hemophilia B.. Blood, 2009, 114, 694-694.	0.6	2
63	Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.. Blood, 2009, 114, 546-546.	0.6	0
64	Assessment of Insertional Mutagenesis Risk Following AAV Vector-Mediated Factor IX Gene Transfer in Mice.. Blood, 2009, 114, 2465-2465.	0.6	0
65	The Development of Novel Hemostatic Bypassing Molecules.. Blood, 2009, 114, SCI-20-SCI-20.	0.6	0
66	Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis. New England Journal of Medicine, 2008, 358, 2240-2248.	13.9	1,941
67	Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle. Molecular Therapy, 2008, 16, 1291-1299.	3.7	89
68	Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII. Blood, 2008, 112, 243-243.	0.6	4
69	Zymogen-Like Factor Xa Variants Restore Thrombin Generation and Effectively Bypass the Intrinsic Pathway in Vitro. Blood, 2008, 112, 240-240.	0.6	3
70	Factor Xa Variants as Novel Bypass Agents for the Treatment of Hemophilia in Murine Models. Blood, 2008, 112, 239-239.	0.6	0
71	The Role of Immunosuppression in Gene- and Cell-Based Treatments for Duchenne Muscular Dystrophy. Molecular Therapy, 2007, 15, 1040-1041.	3.7	4
72	Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007, 110, 2334-2341.	0.6	218

#	ARTICLE	IF	CITATIONS
73	Safety of Recombinant Adeno-Associated Viral Vectors in a Large Animal Model.. Blood, 2007, 110, 2586-2586.	0.6	13
74	Heterogeneous In Vivo Role of Clotting Factors FVIII and FIX in Atherogenesis. Blood, 2007, 110, 3730-3730.	0.6	0
75	Successful Production of Canine FVIII: Biochemical and Functional Characterization in Hemophilia A Dogs.. Blood, 2007, 110, 495-495.	0.6	0
76	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy, 2006, 14, 452-455.	3.7	196
77	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	15.2	1,865
78	Inadvertent Germline Transmission of AAV2 Vector: Findings in a Rabbit Model Correlate with Those in a Human Clinical Trial. Molecular Therapy, 2006, 13, 1064-1073.	3.7	62
79	Long Term Dose-Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9-Mediated FVIII Gene Transfer.. Blood, 2006, 108, 999-999.	0.6	0
80	An Essential Role of the Factor VIII Light Chain in Facilitating Heavy Chain Secretion.. Blood, 2006, 108, 4034-4034.	0.6	0
81	Protease-Activated Receptor 2 (PAR-2) as a Novel Target To Prevent Inhibitor Formation to FIX.. Blood, 2006, 108, 763-763.	0.6	1
82	Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood, 2005, 105, 3458-3464.	0.6	144
83	Factor IX variants improve gene therapy efficacy for hemophilia B. Blood, 2005, 105, 2316-2323.	0.6	71
84	Protease-Activated Receptor-2 (PAR-2) as a Novel Target for Modulating Immune Responses to Neo Antigens Following In Vivo Gene Transfer.. Blood, 2005, 106, 1296-1296.	0.6	1
85	Co-Inheritance of FV Leiden and High Levels of FIX Results in Novel Models for Thrombophilia and Spontaneous Fetal Loss.. Blood, 2005, 106, 1946-1946.	0.6	0
86	Characterization of the Immune Response to Canine Factor IX Following AAV-Mediated Intravascular Gene Delivery to Skeletal Muscle in Hemophilia B Dogs.. Blood, 2005, 106, 1297-1297.	0.6	0
87	Genetic variability of platelet glycoprotein Ib/alpha gene. American Journal of Hematology, 2004, 77, 107-116.	2.0	6
88	Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004, 103, 85-92.	0.6	147
89	A Novel Method of Regional Intravenous Delivery of AAV Vector to Skeletal Muscle Results in Correction of Canine Hemophilia B Phenotype.. Blood, 2004, 104, 3179-3179.	0.6	5
90	A Novel Role of Coagulation Proteases on Viral-Based Gene Transfer Efficacy.. Blood, 2004, 104, 691-691.	0.6	1

#	ARTICLE	IF	CITATIONS
91	In Vivo Evidence of Modulation of the Hemophilia Phenotype by the Factor V Leiden.. Blood, 2004, 104, 693-693.	0.6	0
92	Update on gene therapy for hereditary hematological disorders. Expert Review of Cardiovascular Therapy, 2003, 1, 215-232.	0.6	16
93	AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003, 101, 2963-2972.	0.6	707
94	Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. Journal of Clinical Investigation, 2003, 111, 1347-1356.	3.9	242
95	Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. Journal of Clinical Investigation, 2003, 111, 1347-1356.	3.9	363
96	Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy. Human Gene Therapy, 2002, 13, 1281-1291.	1.4	149
97	Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002, 99, 2670-2676.	0.6	333
98	Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood, 2001, 97, 130-138.	0.6	123
99	Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males. Molecular Therapy, 2001, 4, 586-592.	3.7	152
100	Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null Mutation. Molecular Therapy, 2001, 4, 192-200.	3.7	186
101	Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9. Molecular Therapy, 2001, 4, 201-210.	3.7	133
102	Inherited Thrombophilia as a Risk Factor for the Development of Ischemic Stroke in Young Adults. Thrombosis and Haemostasis, 2000, 83, 229-233.	1.8	108
103	Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics, 2000, 24, 257-261.	9.4	971
104	Prevalence of the mutation C677 T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. , 1998, 78, 332-335.		79
105	The Mutation Ala677 Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis. Thrombosis and Haemostasis, 1997, 77, 0818-0821.	1.8	265
106	Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease. Thrombosis and Haemostasis, 1997, 78, 1430-1433.	1.8	148
107	Association of severe haemophilia A and factor V Leiden: report of three cases. Haemophilia, 1996, 2, 51-53.	1.0	24
108	Factor V Leiden (FVQ 506) is common in a Brazilian population. American Journal of Hematology, 1995, 49, 242-243.	2.0	64

#	ARTICLE	IF	CITATIONS
109	Factor VIII and IX Genes Polymorphisms in a Brazilian Black Population. Thrombosis and Haemostasis, 1993, 70, 371-371.	1.8	5